 | • レポートコード：GIR-105X03354 • 出版社/出版日： / 2021年5月 • レポート形態：英文、PDF、102ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：Pharma & Healthcare |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、心血管疾患治療薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。心血管疾患治療薬の種類別市場規模（ヘパリン、クマディン、セクトラル、ゼベタ、ロプレッサー、トプロロールXL、ノルバスク、ロットレル、その他）、用途別市場規模（虚血性心疾患、脂質異常症、脳卒中、血栓症、アテローム性動脈硬化症、冠状動脈疾患、末梢動脈疾患、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・心血管疾患治療薬の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：AstraZeneca、Johnson＆Johnson、Pfizer、Sanofi、Merck、Daiichi Sankyo Company Limited、Novartis、Bayer、Takeda Pharmaceutical、Hoffmann-La Roche、United Therapeutics Corporation、Actelion Pharmaceuticals、Boehringer Ingelheim、Astellas Pharma ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：ヘパリン、クマディン、セクトラル、ゼベタ、ロプレッサー、トプロロールXL、ノルバスク、ロットレル、その他 ・用途別分析2016年-2026年：虚血性心疾患、脂質異常症、脳卒中、血栓症、アテローム性動脈硬化症、冠状動脈疾患、末梢動脈疾患、その他 ・心血管疾患治療薬の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・心血管疾患治療薬のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・心血管疾患治療薬のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・心血管疾患治療薬の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・心血管疾患治療薬の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Cardiovascular Disease Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Cardiovascular Disease Drugs size is estimated to be xx million in 2020 from USD xx million in 2019, with a change of XX% between 2019 and 2020. The global Cardiovascular Disease Drugs market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Cardiovascular Disease Drugs market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Heparin
Coumadin
Sectral
Zebeta
Lopressor
Toprol XL
Norvasc
Lotrel
Others
Market segment by Application can be divided into
Asischemic Heart Disease
Dyslipidemia
Stroke
Thrombosis
Atherosclerosis
Coronary Artery Diseases
Peripheral Artery Disease
Others
The key market players for global Cardiovascular Disease Drugs market are listed below:
AstraZeneca
Johnson＆Johnson
Pfizer
Sanofi
Merck
Daiichi Sankyo Company Limited
Novartis
Bayer
Takeda Pharmaceutical
Hoffmann-La Roche
United Therapeutics Corporation
Actelion Pharmaceuticals
Boehringer Ingelheim
Astellas Pharma
Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
1 Market Overview
1.1 Cardiovascular Disease Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Cardiovascular Disease Drugs Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 Heparin
1.2.3 Coumadin
1.2.4 Sectral
1.2.5 Zebeta
1.2.6 Lopressor
1.2.7 Toprol XL
1.2.8 Norvasc
1.2.9 Lotrel
1.2.10 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Cardiovascular Disease Drugs Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Asischemic Heart Disease
1.3.3 Dyslipidemia
1.3.4 Stroke
1.3.5 Thrombosis
1.3.6 Atherosclerosis
1.3.7 Coronary Artery Diseases
1.3.8 Peripheral Artery Disease
1.3.9 Others
1.4 Global Cardiovascular Disease Drugs Market Size & Forecast
1.4.1 Global Cardiovascular Disease Drugs Sales in Value (2016-2026))
1.4.2 Global Cardiovascular Disease Drugs Sales in Volume (2016-2026)
1.4.3 Global Cardiovascular Disease Drugs Price by Type (2016-2026) & (USD/Units)
1.5 Global Cardiovascular Disease Drugs Production Capacity Analysis
1.5.1 Global Cardiovascular Disease Drugs Total Production Capacity (2016-2026)
1.5.2 Global Cardiovascular Disease Drugs Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Cardiovascular Disease Drugs Market Drivers
1.6.2 Cardiovascular Disease Drugs Market Restraints
1.6.3 Cardiovascular Disease Drugs Trends Analysis
2 Manufacturers Profiles
2.1 AstraZeneca
2.1.1 AstraZeneca Details
2.1.2 AstraZeneca Major Business
2.1.3 AstraZeneca Cardiovascular Disease Drugs Product and Services
2.1.4 AstraZeneca Cardiovascular Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.2 Johnson＆Johnson
2.2.1 Johnson＆Johnson Details
2.2.2 Johnson＆Johnson Major Business
2.2.3 Johnson＆Johnson Cardiovascular Disease Drugs Product and Services
2.2.4 Johnson＆Johnson Cardiovascular Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.3 Pfizer
2.3.1 Pfizer Details
2.3.2 Pfizer Major Business
2.3.3 Pfizer Cardiovascular Disease Drugs Product and Services
2.3.4 Pfizer Cardiovascular Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.4 Sanofi
2.4.1 Sanofi Details
2.4.2 Sanofi Major Business
2.4.3 Sanofi Cardiovascular Disease Drugs Product and Services
2.4.4 Sanofi Cardiovascular Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.5 Merck
2.5.1 Merck Details
2.5.2 Merck Major Business
2.5.3 Merck Cardiovascular Disease Drugs Product and Services
2.5.4 Merck Cardiovascular Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.6 Daiichi Sankyo Company Limited
2.6.1 Daiichi Sankyo Company Limited Details
2.6.2 Daiichi Sankyo Company Limited Major Business
2.6.3 Daiichi Sankyo Company Limited Cardiovascular Disease Drugs Product and Services
2.6.4 Daiichi Sankyo Company Limited Cardiovascular Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.7 Novartis
2.7.1 Novartis Details
2.7.2 Novartis Major Business
2.7.3 Novartis Cardiovascular Disease Drugs Product and Services
2.7.4 Novartis Cardiovascular Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.8 Bayer
2.8.1 Bayer Details
2.8.2 Bayer Major Business
2.8.3 Bayer Cardiovascular Disease Drugs Product and Services
2.8.4 Bayer Cardiovascular Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.9 Takeda Pharmaceutical
2.9.1 Takeda Pharmaceutical Details
2.9.2 Takeda Pharmaceutical Major Business
2.9.3 Takeda Pharmaceutical Cardiovascular Disease Drugs Product and Services
2.9.4 Takeda Pharmaceutical Cardiovascular Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.10 Hoffmann-La Roche
2.10.1 Hoffmann-La Roche Details
2.10.2 Hoffmann-La Roche Major Business
2.10.3 Hoffmann-La Roche Cardiovascular Disease Drugs Product and Services
2.10.4 Hoffmann-La Roche Cardiovascular Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.11 United Therapeutics Corporation
2.11.1 United Therapeutics Corporation Details
2.11.2 United Therapeutics Corporation Major Business
2.11.3 United Therapeutics Corporation Cardiovascular Disease Drugs Product and Services
2.11.4 United Therapeutics Corporation Cardiovascular Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.12 Actelion Pharmaceuticals
2.12.1 Actelion Pharmaceuticals Details
2.12.2 Actelion Pharmaceuticals Major Business
2.12.3 Actelion Pharmaceuticals Cardiovascular Disease Drugs Product and Services
2.12.4 Actelion Pharmaceuticals Cardiovascular Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.13 Boehringer Ingelheim
2.13.1 Boehringer Ingelheim Details
2.13.2 Boehringer Ingelheim Major Business
2.13.3 Boehringer Ingelheim Cardiovascular Disease Drugs Product and Services
2.13.4 Boehringer Ingelheim Cardiovascular Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.14 Astellas Pharma
2.14.1 Astellas Pharma Details
2.14.2 Astellas Pharma Major Business
2.14.3 Astellas Pharma Cardiovascular Disease Drugs Product and Services
2.14.4 Astellas Pharma Cardiovascular Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
3 Cardiovascular Disease Drugs Sales by Manufacturer
3.1 Global Cardiovascular Disease Drugs Sales in Volume by Manufacturer (2019-2021e)
3.2 Global Cardiovascular Disease Drugs Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in Cardiovascular Disease Drugs
3.4 Market Concentration Rate
3.4.1 Top 3 Cardiovascular Disease Drugs Manufacturer Market Share
3.4.2 Top 6 Cardiovascular Disease Drugs Manufacturer Market Share
3.5 Global Cardiovascular Disease Drugs Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and Cardiovascular Disease Drugs Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Cardiovascular Disease Drugs Market Size by Region
4.1.1 Global Cardiovascular Disease Drugs Sales in Volume by Region (2016-2026)
4.1.2 Global Cardiovascular Disease Drugs Revenue by Region (2016-2026)
4.2 North America Cardiovascular Disease Drugs Revenue (2016-2026)
4.3 Europe Cardiovascular Disease Drugs Revenue (2016-2026)
4.4 Asia-Pacific Cardiovascular Disease Drugs Revenue (2016-2026)
4.5 South America Cardiovascular Disease Drugs Revenue (2016-2026)
4.6 Middle East and Africa Cardiovascular Disease Drugs Revenue (2016-2026)
5 Market Segment by Type
5.1 Global Cardiovascular Disease Drugs Sales in Volume by Type (2016-2026)
5.2 Global Cardiovascular Disease Drugs Revenue by Type (2016-2026)
5.3 Global Cardiovascular Disease Drugs Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global Cardiovascular Disease Drugs Sales in Volume by Application (2016-2026)
6.2 Global Cardiovascular Disease Drugs Revenue by Application (2016-2026)
6.3 Global Cardiovascular Disease Drugs Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America Cardiovascular Disease Drugs Sales by Type (2016-2026)
7.2 North America Cardiovascular Disease Drugs Sales by Application (2016-2026)
7.3 North America Cardiovascular Disease Drugs Market Size by Country
7.3.1 North America Cardiovascular Disease Drugs Sales in Volume by Country (2016-2026)
7.3.2 North America Cardiovascular Disease Drugs Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe Cardiovascular Disease Drugs Sales by Type (2016-2026)
8.2 Europe Cardiovascular Disease Drugs Sales by Application (2016-2026)
8.3 Europe Cardiovascular Disease Drugs Market Size by Country
8.3.1 Europe Cardiovascular Disease Drugs Sales in Volume by Country (2016-2026)
8.3.2 Europe Cardiovascular Disease Drugs Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific Cardiovascular Disease Drugs Sales by Type (2016-2026)
9.2 Asia-Pacific Cardiovascular Disease Drugs Sales by Application (2016-2026)
9.3 Asia-Pacific Cardiovascular Disease Drugs Market Size by Region
9.3.1 Asia-Pacific Cardiovascular Disease Drugs Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific Cardiovascular Disease Drugs Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America Cardiovascular Disease Drugs Sales by Type (2016-2026)
10.2 South America Cardiovascular Disease Drugs Sales by Application (2016-2026)
10.3 South America Cardiovascular Disease Drugs Market Size by Country
10.3.1 South America Cardiovascular Disease Drugs Sales in Volume by Country (2016-2026)
10.3.2 South America Cardiovascular Disease Drugs Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Cardiovascular Disease Drugs Sales by Type (2016-2026)
11.2 Middle East & Africa Cardiovascular Disease Drugs Sales by Application (2016-2026)
11.3 Middle East & Africa Cardiovascular Disease Drugs Market Size by Country
11.3.1 Middle East & Africa Cardiovascular Disease Drugs Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa Cardiovascular Disease Drugs Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Cardiovascular Disease Drugs Typical Distributors
12.3 Cardiovascular Disease Drugs Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Table 1. Global Cardiovascular Disease Drugs Revenue by Type, (USD Million), 2021-2026
Table 2. Global Cardiovascular Disease Drugs Revenue by Application, (USD Million), 2021-2026
Table 3. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 4. AstraZeneca Major Business
Table 5. AstraZeneca Cardiovascular Disease Drugs Product and Services
Table 6. AstraZeneca Cardiovascular Disease Drugs Sales (K Units), Price (USD/Units), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. Johnson＆Johnson Basic Information, Manufacturing Base and Competitors
Table 8. Johnson＆Johnson Major Business
Table 9. Johnson＆Johnson Cardiovascular Disease Drugs Product and Services
Table 10. Johnson＆Johnson Cardiovascular Disease Drugs Sales (K Units), Price (USD/Units), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. Pfizer Basic Information, Manufacturing Base and Competitors
Table 12. Pfizer Major Business
Table 13. Pfizer Cardiovascular Disease Drugs Product and Services
Table 14. Pfizer Cardiovascular Disease Drugs Sales (K Units), Price (USD/Units), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. Sanofi Basic Information, Manufacturing Base and Competitors
Table 16. Sanofi Major Business
Table 17. Sanofi Cardiovascular Disease Drugs Product and Services
Table 18. Sanofi Cardiovascular Disease Drugs Sales (K Units), Price (USD/Units), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 19. Merck Basic Information, Manufacturing Base and Competitors
Table 20. Merck Major Business
Table 21. Merck Cardiovascular Disease Drugs Product and Services
Table 22. Merck Cardiovascular Disease Drugs Sales (K Units), Price (USD/Units), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 23. Daiichi Sankyo Company Limited Basic Information, Manufacturing Base and Competitors
Table 24. Daiichi Sankyo Company Limited Major Business
Table 25. Daiichi Sankyo Company Limited Cardiovascular Disease Drugs Product and Services
Table 26. Daiichi Sankyo Company Limited Cardiovascular Disease Drugs Sales (K Units), Price (USD/Units), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 27. Novartis Basic Information, Manufacturing Base and Competitors
Table 28. Novartis Major Business
Table 29. Novartis Cardiovascular Disease Drugs Product and Services
Table 30. Novartis Cardiovascular Disease Drugs Sales (K Units), Price (USD/Units), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 31. Bayer Basic Information, Manufacturing Base and Competitors
Table 32. Bayer Major Business
Table 33. Bayer Cardiovascular Disease Drugs Product and Services
Table 34. Bayer Cardiovascular Disease Drugs Sales (K Units), Price (USD/Units), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 35. Takeda Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 36. Takeda Pharmaceutical Major Business
Table 37. Takeda Pharmaceutical Cardiovascular Disease Drugs Product and Services
Table 38. Takeda Pharmaceutical Cardiovascular Disease Drugs Sales (K Units), Price (USD/Units), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 39. Hoffmann-La Roche Basic Information, Manufacturing Base and Competitors
Table 40. Hoffmann-La Roche Major Business
Table 41. Hoffmann-La Roche Cardiovascular Disease Drugs Product and Services
Table 42. Hoffmann-La Roche Cardiovascular Disease Drugs Sales (K Units), Price (USD/Units), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 43. United Therapeutics Corporation Basic Information, Manufacturing Base and Competitors
Table 44. United Therapeutics Corporation Major Business
Table 45. United Therapeutics Corporation Cardiovascular Disease Drugs Product and Services
Table 46. United Therapeutics Corporation Cardiovascular Disease Drugs Sales (K Units), Price (USD/Units), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 47. Actelion Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 48. Actelion Pharmaceuticals Major Business
Table 49. Actelion Pharmaceuticals Cardiovascular Disease Drugs Product and Services
Table 50. Actelion Pharmaceuticals Cardiovascular Disease Drugs Sales (K Units), Price (USD/Units), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 51. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
Table 52. Boehringer Ingelheim Major Business
Table 53. Boehringer Ingelheim Cardiovascular Disease Drugs Product and Services
Table 54. Boehringer Ingelheim Cardiovascular Disease Drugs Sales (K Units), Price (USD/Units), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 55. Astellas Pharma Basic Information, Manufacturing Base and Competitors
Table 56. Astellas Pharma Major Business
Table 57. Astellas Pharma Cardiovascular Disease Drugs Product and Services
Table 58. Astellas Pharma Cardiovascular Disease Drugs Sales (K Units), Price (USD/Units), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 59. Global Cardiovascular Disease Drugs Sales by Manufacturer (2019-2021e) & (K Units)
Table 60. Global Cardiovascular Disease Drugs Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 61. Market Position of Manufacturers in Cardiovascular Disease Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 62. Global Cardiovascular Disease Drugs Production Capacity by Company, (K Units): 2020 VS 2021
Table 63. Head Office and Cardiovascular Disease Drugs Production Site of Key Manufacturer
Table 64. Global Cardiovascular Disease Drugs Sales by Region (2016-2021e) & (K Units)
Table 65. Global Cardiovascular Disease Drugs Sales by Region (2021-2026) & (K Units)
Table 66. Global Cardiovascular Disease Drugs Revenue by Region (2016-2021e) & (USD Million)
Table 67. Global Cardiovascular Disease Drugs Revenue by Region (2021-2026) & (USD Million)
Table 68. Global Cardiovascular Disease Drugs Sales by Type (2016-2021e) & (K Units)
Table 69. Global Cardiovascular Disease Drugs Sales by Type (2021-2026) & (K Units)
Table 70. Global Cardiovascular Disease Drugs Revenue by Type (2016-2021e) & (USD Million)
Table 71. Global Cardiovascular Disease Drugs Revenue by Type (2021-2026) & (USD Million)
Table 72. Global Cardiovascular Disease Drugs Price by Type (2016-2021e) & (USD/Units)
Table 73. Global Cardiovascular Disease Drugs Price by Type (2021-2026) & (USD/Units)
Table 74. Global Cardiovascular Disease Drugs Sales by Application (2016-2021e) & (K Units)
Table 75. Global Cardiovascular Disease Drugs Sales by Application (2021-2026) & (K Units)
Table 76. Global Cardiovascular Disease Drugs Revenue by Application (2016-2021e) & (USD Million)
Table 77. Global Cardiovascular Disease Drugs Revenue by Application (2021-2026) & (USD Million)
Table 78. Global Cardiovascular Disease Drugs Price by Application (2016-2021e) & (USD/Units)
Table 79. Global Cardiovascular Disease Drugs Price by Application (2021-2026) & (USD/Units)
Table 80. North America Cardiovascular Disease Drugs Sales by Country (2016-2021e) & (K Units)
Table 81. North America Cardiovascular Disease Drugs Sales by Country (2021-2026) & (K Units)
Table 82. North America Cardiovascular Disease Drugs Revenue by Country (2016-2021e) & (USD Million)
Table 83. North America Cardiovascular Disease Drugs Revenue by Country (2021-2026) & (USD Million)
Table 84. North America Cardiovascular Disease Drugs Sales by Type (2016-2021e) & (K Units)
Table 85. North America Cardiovascular Disease Drugs Sales by Type (2021-2026) & (K Units)
Table 86. North America Cardiovascular Disease Drugs Sales by Application (2016-2021e) & (K Units)
Table 87. North America Cardiovascular Disease Drugs Sales by Application (2021-2026) & (K Units)
Table 88. Europe Cardiovascular Disease Drugs Sales by Country (2016-2021e) & (K Units)
Table 89. Europe Cardiovascular Disease Drugs Sales by Country (2021-2026) & (K Units)
Table 90. Europe Cardiovascular Disease Drugs Revenue by Country (2016-2021e) & (USD Million)
Table 91. Europe Cardiovascular Disease Drugs Revenue by Country (2021-2026) & (USD Million)
Table 92. Europe Cardiovascular Disease Drugs Sales by Type (2016-2021e) & (K Units)
Table 93. Europe Cardiovascular Disease Drugs Sales by Type (2021-2026) & (K Units)
Table 94. Europe Cardiovascular Disease Drugs Sales by Application (2016-2021e) & (K Units)
Table 95. Europe Cardiovascular Disease Drugs Sales by Application (2021-2026) & (K Units)
Table 96. Asia-Pacific Cardiovascular Disease Drugs Sales by Region (2016-2021e) & (K Units)
Table 97. Asia-Pacific Cardiovascular Disease Drugs Sales by Region (2021-2026) & (K Units)
Table 98. Asia-Pacific Cardiovascular Disease Drugs Revenue by Region (2016-2021e) & (USD Million)
Table 99. Asia-Pacific Cardiovascular Disease Drugs Revenue by Region (2021-2026) & (USD Million)
Table 100. Asia-Pacific Cardiovascular Disease Drugs Sales by Type (2016-2021e) & (K Units)
Table 101. Asia-Pacific Cardiovascular Disease Drugs Sales by Type (2021-2026) & (K Units)
Table 102. Asia-Pacific Cardiovascular Disease Drugs Sales by Application (2016-2021e) & (K Units)
Table 103. Asia-Pacific Cardiovascular Disease Drugs Sales by Application (2021-2026) & (K Units)
Table 104. South America Cardiovascular Disease Drugs Sales by Country (2016-2021e) & (K Units)
Table 105. South America Cardiovascular Disease Drugs Sales by Country (2021-2026) & (K Units)
Table 106. South America Cardiovascular Disease Drugs Revenue by Country (2016-2021e) & (USD Million)
Table 107. South America Cardiovascular Disease Drugs Revenue by Country (2021-2026) & (USD Million)
Table 108. South America Cardiovascular Disease Drugs Sales by Type (2016-2021e) & (K Units)
Table 109. South America Cardiovascular Disease Drugs Sales by Type (2021-2026) & (K Units)
Table 110. South America Cardiovascular Disease Drugs Sales by Application (2016-2021e) & (K Units)
Table 111. South America Cardiovascular Disease Drugs Sales by Application (2021-2026) & (K Units)
Table 112. Middle East & Africa Cardiovascular Disease Drugs Sales by Country (2016-2021e) & (K Units)
Table 113. Middle East & Africa Cardiovascular Disease Drugs Sales by Country (2021-2026) & (K Units)
Table 114. Middle East & Africa Cardiovascular Disease Drugs Revenue by Country (2016-2021e) & (USD Million)
Table 115. Middle East & Africa Cardiovascular Disease Drugs Revenue by Country (2021-2026) & (USD Million)
Table 116. Middle East & Africa Cardiovascular Disease Drugs Sales by Type (2016-2021e) & (K Units)
Table 117. Middle East & Africa Cardiovascular Disease Drugs Sales by Type (2021-2026) & (K Units)
Table 118. Middle East & Africa Cardiovascular Disease Drugs Sales by Application (2016-2021e) & (K Units)
Table 119. Middle East & Africa Cardiovascular Disease Drugs Sales by Application (2021-2026) & (K Units)
Table 120. Direct Channel Pros & Cons
Table 121. Indirect Channel Pros & Cons
Table 122. Cardiovascular Disease Drugs Typical Distributors
Table 123. Cardiovascular Disease Drugs Typical Customers
List of Figures
Figure 1. Cardiovascular Disease Drugs Picture
Figure 2. Global Cardiovascular Disease Drugs Sales Market Share by Type in 2020
Figure 3. Heparin
Figure 4. Coumadin
Figure 5. Sectral
Figure 6. Zebeta
Figure 7. Lopressor
Figure 8. Toprol XL
Figure 9. Norvasc
Figure 10. Lotrel
Figure 11. Others
Figure 12. Global Cardiovascular Disease Drugs Sales Market Share by Application in 2020
Figure 13. Asischemic Heart Disease
Figure 14. Dyslipidemia
Figure 15. Stroke
Figure 16. Thrombosis
Figure 17. Atherosclerosis
Figure 18. Coronary Artery Diseases
Figure 19. Peripheral Artery Disease
Figure 20. Others
Figure 21. Global Cardiovascular Disease Drugs Market Size, (USD Million) & (K Units): 2020 VS 2021 VS 2026
Figure 22. Global Cardiovascular Disease Drugs Market Size and Forecast (2016-2026) & (USD Million)
Figure 23. United States Cardiovascular Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 24. Canada Cardiovascular Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 25. Mexico Cardiovascular Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 26. Germany Cardiovascular Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 27. France Cardiovascular Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 28. United Kingdom Cardiovascular Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 29. Russia Cardiovascular Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 30. Italy Cardiovascular Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 31. China Cardiovascular Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 32. Japan Cardiovascular Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 33. Korea Cardiovascular Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 34. India Cardiovascular Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 35. Southeast Asia Cardiovascular Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 36. Australia Cardiovascular Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 37. Brazil Cardiovascular Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 38. Egypt Cardiovascular Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 39. Saudi Arabia Cardiovascular Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 40. South Africa Cardiovascular Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 41. Turkey Cardiovascular Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 42. Global Cardiovascular Disease Drugs Sales (2016-2026) & (K Units)
Figure 43. Global Cardiovascular Disease Drugs Production Capacity (2016-2026) & (K Units)
Figure 44. Global Cardiovascular Disease Drugs Production Capacity by Geographic Region: 2020 VS 2021
Figure 45. Cardiovascular Disease Drugs Market Drivers
Figure 46. Cardiovascular Disease Drugs Market Restraints
Figure 47. Cardiovascular Disease Drugs Market Trends
Figure 48. Global Cardiovascular Disease Drugs Sales Market Share by Manufacturer in 2020
Figure 49. Global Cardiovascular Disease Drugs Revenue Market Share by Manufacturer in 2020
Figure 50. Cardiovascular Disease Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 51. Top 3 Cardiovascular Disease Drugs Manufacturer (Revenue) Market Share in 2020
Figure 52. Top 6 Cardiovascular Disease Drugs Manufacturer (Revenue) Market Share in 2020
Figure 53. Global Cardiovascular Disease Drugs Sales Market Share by Region (2016-2026)
Figure 54. Global Cardiovascular Disease Drugs Revenue Market Share by Region (2016-2026)
Figure 55. North America Cardiovascular Disease Drugs Revenue (2016-2026) & (USD Million)
Figure 56. Europe Cardiovascular Disease Drugs Revenue (2016-2026) & (USD Million)
Figure 57. Asia-Pacific Cardiovascular Disease Drugs Revenue (2016-2026) & (USD Million)
Figure 58. South America Cardiovascular Disease Drugs Revenue (2016-2026) & (USD Million)
Figure 59. Middle East & Africa Cardiovascular Disease Drugs Revenue (2016-2026) & (USD Million)
Figure 60. Global Cardiovascular Disease Drugs Sales Market Share by Type (2016-2026)
Figure 61. Global Cardiovascular Disease Drugs Revenue Market Share by Type (2016-2026)
Figure 62. Global Cardiovascular Disease Drugs Price by Type (2016-2026) & (USD/Units)
Figure 63. Global Cardiovascular Disease Drugs Sales Market Share by Application (2016-2026)
Figure 64. Global Cardiovascular Disease Drugs Revenue Market Share by Application (2016-2026)
Figure 65. Global Cardiovascular Disease Drugs Price by Application (2016-2026) & (USD/Units)
Figure 66. North America Cardiovascular Disease Drugs Sales Market Share by Country (2016-2026)
Figure 67. North America Cardiovascular Disease Drugs Revenue Market Share by Country (2016-2026)
Figure 68. North America Cardiovascular Disease Drugs Sales Market Share by Type (2016-2026)
Figure 69. North America Cardiovascular Disease Drugs Sales Market Share by Application (2016-2026)
Figure 70. Europe Cardiovascular Disease Drugs Sales Market Share by Country (2016-2026)
Figure 71. Europe Cardiovascular Disease Drugs Revenue Market Share by Country (2016-2026)
Figure 72. Europe Cardiovascular Disease Drugs Sales Market Share by Type (2016-2026)
Figure 73. Europe Cardiovascular Disease Drugs Sales Market Share by Application (2016-2026)
Figure 74. Asia-Pacific Cardiovascular Disease Drugs Sales Market Share by Region (2016-2026)
Figure 75. Asia-Pacific Cardiovascular Disease Drugs Revenue Market Share by Region (2016-2026)
Figure 76. Asia-Pacific Cardiovascular Disease Drugs Sales Market Share by Region (2016-2026)
Figure 77. Asia-Pacific Cardiovascular Disease Drugs Sales Market Share by Application (2016-2026)
Figure 78. South America Cardiovascular Disease Drugs Sales Market Share by Country (2016-2026)
Figure 79. South America Cardiovascular Disease Drugs Revenue Market Share by Country (2016-2026)
Figure 80. South America Cardiovascular Disease Drugs Sales Market Share by Type (2016-2026)
Figure 81. South America Cardiovascular Disease Drugs Sales Market Share by Application (2016-2026)
Figure 82. Middle East & Africa Cardiovascular Disease Drugs Sales Market Share by Country (2016-2026)
Figure 83. Middle East & Africa Cardiovascular Disease Drugs Revenue Market Share by Country (2016-2026)
Figure 84. Middle East & Africa Cardiovascular Disease Drugs Sales Market Share by Type (2016-2026)
Figure 85. Middle East & Africa Cardiovascular Disease Drugs Sales Market Share by Application (2016-2026)
Figure 86. Sales Channel: Direct Channel vs Indirect Channel
Figure 87. Methodology
Figure 88. Research Process and Data Source
虚血性心疾患（IHD）薬の世界市場予測 2023年：メーカー別、地域別、種類・用途別 Ischemic heart disease (IHD), refers to a group of diseases which includes stable angina, unstable angina, myocardial infarction, and sudden cardiac death. It is within the group of cardiovascular diseases of which it is the most common type. A common symptom is chest pain or discomfort which may tr…- 心臓血管疾患のモニタリングと診断装置の世界市場予測 2023年：メーカー別、地域別、種類・用途別 Cardio Vascular Diseases or CVD is the world’s leading cause of death in men and women and these deaths are due to heart failure, congenital heart disease, peripheral vascular disease, cardiomyopathy, coronary heart disease and stroke. Cardio vascular monitoring devices help in identifying electrica…
- 世界のゴーシェ病治療薬市場 2021：企業別、地域別、種類・用途別 The Gaucher Disease Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulatio…
- パーキンソン病の薬の世界市場2018-2025 Parkinson's disease is a type of progressive movement disorder, characterized by muscle rigidity, and tremors. In 2018, the global Parkinson’s Disease Drugs market size was xx million US$ and is forecast to xx million US in 2025, growing at a CAGR of xx% from 2018. In this study, 2017 has been consi…
- 慢性腎疾患（CKD）薬の世界市場予測 2023年：メーカー別、地域別、種類・用途別 Chronic Kidney Disease (CKD) Drugs are drugs for Chronic kidney disease, which also called chronic kidney failure, describes the gradual loss of kidney function. Scope of the Report: This report focuses on the Chronic Kidney Disease (CKD) Drugs in global market, especially in North America, Europe a…